KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Account Payables (2016 - 2025)

Nektar Therapeutics has reported Change in Account Payables over the past 16 years, most recently at -$4.8 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$4.8 million for Q4 2025, down 229.86% from a year ago — trailing twelve months through Dec 2025 was -$625000.0 (down 123.43% YoY), and the annual figure for FY2025 was -$625000.0, down 123.43%.
  • Change in Account Payables for Q4 2025 was -$4.8 million at Nektar Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Change in Account Payables for NKTR hit a ceiling of $7.3 million in Q4 2022 and a floor of -$12.9 million in Q4 2021.
  • Median Change in Account Payables over the past 5 years was $252000.0 (2022), compared with a mean of -$471400.0.
  • Biggest five-year swings in Change in Account Payables: plummeted 552.73% in 2023 and later soared 748.79% in 2025.
  • Nektar Therapeutics' Change in Account Payables stood at -$12.9 million in 2021, then skyrocketed by 156.33% to $7.3 million in 2022, then fell by 11.57% to $6.4 million in 2023, then tumbled by 42.72% to $3.7 million in 2024, then tumbled by 229.86% to -$4.8 million in 2025.
  • The last three reported values for Change in Account Payables were -$4.8 million (Q4 2025), $1.3 million (Q3 2025), and -$3.5 million (Q2 2025) per Business Quant data.